Table of Contents
Volume 6 | Supplement 1
Publication Date: December 2004- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Introduction | ||
S6 |
Emerging Role of Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer Chandra P. Belani |
|
Contributions | ||
S7-S19 |
Overview of the Current Status of Human Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Roy S. Herbst, Alan B. Sandler |
|
S20-S23 |
Phase II Clinical Trial Data with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer Romàn Pérez-Soler |
|
S24-S29 |
Select Clinical Trials of Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer with Emphasis on Phase III Outcomes L. Minerva Burgos Fuster, Alan B. Sandler |
|
S30-S34 |
Predictors of Sensitivity and Resistance to Epidermal Growth Factor Receptor Inhibitors Sofia Perea, Manuel Hidalgo |
|
S35-S42 |
Effect of Epidermal Growth Factor Receptor Mutations on the Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Target-Based Populations for Target-Based Drugs Emiliano Calvo, Eric K. Rowinsky |
|
S43-S47 |
Role of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Bronchoalveolar Jyoti D. Patel |
|